The obesity medicine landscape shifted again in late 2025 when Eli Lilly announced results from TRIUMPH-4, the Phase 3 clinical trial evaluating retatrutide (LY3437943) for chronic weight management. The headline figure — 28.7% mean body weight loss at the 12mg dose over 68 weeks — is the largest mean weight reduction ever recorded in a Phase 3 obesity trial. According to reporting from PharmaWire, Eli Lilly shares climbed approximately 4% following the data release, with analysts and investors widely interpreting the results as confirmation of Lilly's continued dominance in the rapidly expanding weight-loss drug market. Retatrutide is broadly described as Eli Lilly's next-generation obesity treatment — and the clinical numbers are beginning to justify that characterization.
Retatrutide is a triple hormone receptor agonist, simultaneously activating receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple-receptor mechanism — sometimes called "triple G" in patient communities — is what distinguishes retatrutide from earlier agents that target only one or two of these pathways. The glucagon receptor component is particularly noteworthy: it increases energy expenditure and promotes fat breakdown in ways that single or dual agonists cannot replicate, which may help explain why the efficacy ceiling appears higher with retatrutide than with any currently approved therapy.
In TRIUMPH-4, the 12mg maintenance dose followed a careful titration schedule: 2mg during weeks 1–4, 4mg during weeks 5–8, 6mg during weeks 9–12, 9mg during weeks 13–16, and full 12mg maintenance beginning at week 17. This stepwise approach is designed to minimize gastrointestinal side effects during early treatment. Notably, discontinuation rates were higher in the active arms than in placebo — 18.2% at 12mg and 12.2% at 9mg versus 4.0% with placebo. Among the reasons for discontinuation, some participants stopped due to what was perceived as excessive weight loss, an unprecedented phenomenon in obesity pharmacotherapy. Dysesthesia — an abnormal skin sensation — was reported in 20.9% of participants at 12mg and 8.8% at 9mg, compared to just 0.7% in the placebo group, a finding that clinicians are monitoring closely as Phase 3 data matures. A peer-reviewed Phase 3 publication is pending as of April 2026.
To appreciate what retatrutide's results represent, it helps to place the data within the broader context of approved therapies. The table below compares mean weight loss outcomes across the pivotal trials of the three most clinically relevant agents.
| Drug | Mechanism | Pivotal Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | GLP-1 / GIP / glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | ~28.7% |
Each generation of agents has meaningfully outperformed the last. Semaglutide, a GLP-1 receptor agonist, demonstrated that pharmacotherapy could achieve double-digit weight loss at scale. Tirzepatide's dual GLP-1/GIP mechanism pushed that ceiling to roughly 20.9% at the highest dose. Retatrutide's addition of glucagon receptor agonism appears to produce yet another step-change in efficacy.
The Phase 2 data — published in the New England Journal of Medicine in 2023 by Jastreboff et al. — provided the first signal of this potential. Across 338 adults with obesity (BMI ≥30, or ≥27 with a weight-related comorbidity) treated over 48 weeks, participants on the 8mg dose lost a mean of approximately 22.8% of body weight, and 70% of participants in that arm achieved at least 20% weight reduction. At 12mg, mean weight loss reached approximately 24.2%, with 48% of participants losing 25% or more of their body weight. These figures were unprecedented for a pharmacological agent at Phase 2. The Phase 3 TRIUMPH-4 results not only replicated but exceeded those findings — reinforcing that the Phase 2 signal was real and durable.
Beyond the scale on the wall, retatrutide's Phase 2 data also showed meaningful improvements in cardiometabolic markers. Fasting triglycerides fell by approximately 34% at 12mg versus just 3.1% with placebo at week 24. LDL cholesterol dropped by 15.6–16.9% in the 8mg arms. Total cholesterol declined by approximately 17.3% at the 12mg dose. For patients who carry both obesity and metabolic disease risk, these accompanying benefits are clinically meaningful in their own right.
Many people commonly referred to as part of the retatrutide patient community use the shorthand reta when discussing the drug, a term that reflects how closely this population has been following the science. The concept of food noise — the persistent, intrusive mental preoccupation with eating that many people with obesity describe — is frequently cited by patients as one of the most disabling aspects of the condition. GLP-1–based therapies have been associated with meaningful reductions in food noise, and the expectation within patient communities is that reta's more comprehensive receptor profile may extend this benefit further, though head-to-head data comparing subjective appetite experiences across agents are not yet available.
The honest answer is that the timeline to FDA approval remains uncertain. As of April 2026, Eli Lilly has not yet filed a New Drug Application (NDA) for retatrutide, and no official FDA approval date has been publicly confirmed. Phase 3 peer-reviewed data are still pending publication. What is clear is that the regulatory pathway is advancing: TRIUMPH-4 has produced the kind of Phase 3 efficacy and safety dataset that supports NDA submission, and Lilly has every commercial incentive to move efficiently through the process. The question is not whether retatrutide will reach the market but when — and under what conditions the healthcare system will provide access to it.
For patients who have followed this drug's journey from early Phase 1 signals through the landmark 2023 NEJM publication and now into Phase 3, the TRIUMPH-4 results offer genuine reasons for optimism. A 28.7% mean weight loss over 68 weeks represents the kind of outcome that previously required bariatric surgery. The proportion of patients achieving 25% or more body weight reduction in Phase 2 — up to 48% at 12mg — suggests that a large share of people treated with retatrutide could experience transformative, not merely incremental, changes in their health.
Side effects, particularly dysesthesia at higher doses and GI symptoms during titration, deserve honest discussion with a qualified clinician. The TRIUMPH-4 discontinuation data make clear that tolerability is a real consideration, not a footnote. Individual clinical circumstances, medication history, and comorbidities will all shape whether and at what dose retatrutide is appropriate for any given patient.
If retatrutide's emerging clinical profile resonates, the best step right now is to stay informed and be positioned when access becomes available. glp3md.com maintains a dedicated retatrutide waitlist so that interested individuals are among the first to receive updates as the regulatory and access landscape evolves. Join the waitlist at glp3md.com to receive evidence-based clinical updates directly. Please note: joining the waitlist involves no commitment and carries no promise of medication access, treatment, or a prescription. Retatrutide is not FDA-approved, and waitlist membership is for informational purposes only.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.